SCHEMBL1926045

SCHEMBL1926045

O=S(=O)(Cl)c1sccc1Cl

nearest known ligand 0.32

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.32
HSD17B10 Q99714 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
GAA P10253 3/20 0.32
MAPK1 P28482 1/20 0.32
ATM Q13315 1/20 0.32
MAPT P10636 3/20 0.32
CES1 P23141 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
TRPV4 Q9HBA0 1/20 0.31
PDPK1 O15530 1/20 0.31
USP2 O75604 1/20 0.30
ESR2 Q92731 1/20 0.30
AGTR1 P30556 1/20 0.30
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1927963 0.81 GAA (0.41) TDP1GAAMAPK1ATMLMNA
SCHEMBL1927961 0.79 GAA (0.31) ALDH1A1GAAMAPK1ATMMAPT
SCHEMBL3467639 0.79 MAPT (0.34) ALDH1A1HSD17B10TDP1GAAMAPK1
Hydrochloric Acid SCHEMBL28047275 0.77 GAA (0.33) ALDH1A1HSD17B10TDP1GAAMAPK1
SCHEMBL5559189 0.76 LMNA (0.33) ALDH1A1HSD17B10TDP1CES1KMT2A
SCHEMBL23569857 0.74 PTGS2 (0.32) ALDH1A1HSD17B10TDP1CES1
SCHEMBL2459334 0.74 GSK3B (0.38) ALDH1A1HSD17B10TDP1GAAATM
SCHEMBL1927038 0.74 ALDH1A1 (0.31) ALDH1A1HSD17B10TDP1CES1
SCHEMBL10934086 0.71
SCHEMBL27174939 0.71 CA2 (0.34) TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117050053-A Novel thiophene antitumor compound and preparation method and application thereof 北京中医药大学 2023-11-14 CN claimed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-11-12 US disclosed
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-09-26 US disclosed
US-20240308989-A1 PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS ORION CORP (FI) 2024-09-19 US disclosed
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-08-13 US disclosed
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2024-07-18 US disclosed
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2024-07-18 US disclosed
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2024-07-18 US disclosed
CN-101180299-A Ethynyl-pyrazolopyrimidine derivatives as MGLUR2 antagonists HOFFMANN LA ROCHE (CH) 2008-05-14 CN disclosed
CN-101081845-A Substituted sulphone and sulphonamide compounds useful for the treatment of obesity, type II diabetes and cns disorders BIOVITRUM AB (SE) 2007-12-05 CN disclosed
CN-101035765-A Sulfonamide derivatives HOFFMANN LA ROCHE (CH) 2007-09-12 CN disclosed
WO-2007098030-A1 SELECTIVE N-SULFONYLATION OF 2-AMINO TRIFLUOROALKYL SUBSTITUTED ALCOHOLS WYETH (US) 2007-08-30 WO disclosed
CN-1972918-A Pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-05-30 CN disclosed
CN-1907982-A New compounds useful for the treatment of obesity,type II diabetes and CNS disorders BIOVITRUM AB (SE) 2007-02-07 CN disclosed
EP-1608638-A1 FLUORO-AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF Wyeth (US) 2005-12-28 EP disclosed
CN-1662521-A Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders BIOVITRUM AB (SE) 2005-08-31 CN disclosed
WO-2004092155-A1 FLUORO-AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF WYETH (US) 2004-10-28 WO disclosed
CN-1265670-A Dipeptides and related compounds that inhibit VLA-4 mediated leukocyte adhesion ELAND PHARMACEUTICALS CO (US) 2000-09-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS ALDH1A1 1636/4885HSD17B10 4042/4885TDP1 510/4885
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS ALDH1A1 1636/4885HSD17B10 4042/4885TDP1 510/4885
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS ALDH1A1 1636/4885HSD17B10 4042/4885TDP1 510/4885
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS ALDH1A1 1636/4885HSD17B10 4042/4885TDP1 510/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD ALDH1A1 1619/4885HSD17B10 4005/4885TDP1 489/4885
US-20240239801-A1 PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF NRAS, BRAF, KRAS ALDH1A1 1786/4885HSD17B10 4490/4885TDP1 510/4885
US-20240308989-A1 PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS CYP11B1, CYP11B2, CYP4A11 ALDH1A1 161/4885HSD17B10 89/4885TDP1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.